Physician profile
Stephen A Rafelson
NPI 1417997875
$3,313.74
in general payments reported to CMS, 2019-2025
25 companies · $616 in 2025
The $616 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $584 · 2020: $13.33 · 2021: $99.00 · 2022: $46.48 · 2023: $613 · 2024: $1,343 · 2025: $616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,535 · Education: $36.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,535.01 |
| Education | $36.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $672.03 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $500.89 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $433.94 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $313.24 | 2019-2025 | Entyvio, Eohilia |
| Braintree Laboratories, INC. | $186.47 | 2019-2025 | Suflave |
| Ironwood Pharmaceuticals, INC | $142.14 | 2023-2025 | Linzess |
| Pfizer INC. | $129.77 | 2019-2025 | |
| Gilead Sciences, INC. | $108.97 | 2019-2025 | |
| Celgene Corporation | $102.79 | 2023-2024 | Zeposia |
| Qol Medical, LLC | $101.62 | 2019-2025 | Sucraid |
| Aimmune Therapeutics, INC. | $78.95 | 2024-2025 | Zenpep |
| Genzyme Corporation | $75.71 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $67.60 | 2024 | Dificid |
| Lilly USA, LLC | $60.32 | 2024-2025 | Omvoh |
| Allergan, INC. | $60.05 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Digestive Care, INC. | $44.39 | 2024 | Pertzye |
| Celltrion USA INC. | $42.58 | 2024 | Zymfentra, Vegzelma |
| Ardelyx, INC. | $42.18 | 2023-2024 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $36.94 | 2023 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $27.24 | 2024 | Iqirvo |
| Daiichi Sankyo INC. | $24.85 | 2025 | Vanflyta |
| Phathom Pharmaceuticals, INC. | $18.24 | 2024 | Voquezna |
| Shionogi INC | $16.68 | 2019 | |
| Intercept Pharmaceuticals, INC. | $16.15 | 2024 | |
| Erbe USA INC | $10.00 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Rafelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.